- Investopedia•16 days ago
Tetraphase’s antibiotic drug candidate may top annual sales of $700 million for its two indications.
- Reuters•20 days ago
Tetraphase Pharmaceuticals Inc Chief Executive Guy Macdonald said annual sales of the company's lead experimental antibiotic for serious bacterial infections could climb as high as $700 million if approved. The antibiotic, eravacycline, is being studied in a pivotal 450-patient Phase III trial for intra-abdominal infections. Tetraphase expects to have the data in the fourth quarter after which it will apply for U.S. approval that could come in 2018.
- GlobeNewswire•last monthTetraphase Pharmaceuticals Doses First Patient in IGNITE3 Phase 3 Clinical Trial of Once-daily IV Eravacycline in cUTI
WATERTOWN, Mass., Jan. 17, 2017-- Tetraphase Pharmaceuticals, Inc. today announced dosing of the first patient in IGNITE3, the Company’ s phase 3 clinical trial evaluating the efficacy and safety of once-daily ...
TTPH : Summary for Tetraphase Pharmaceuticals, Inc - Yahoo Finance
Tetraphase Pharmaceuticals, Inc. (TTPH)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||5.34 x 400|
|Ask||5.35 x 1200|
|Day's Range||5.17 - 5.44|
|52 Week Range||3.11 - 6.28|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-2.67|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|